British journal of cancer · 2026
Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Choi Eunji, Luo Sophia, Ding Victoria Y, Graber-Nadich Anna, Wu Julie T, Popat Rita, Cheng Iona, Neal Joel W, Wakelee Heather A, Han Summer S
Аннотация
BACKGROUND: Lung cancer survivors have a high risk of second primary lung cancer (SPLC). While air pollution is associated with the risk of initial primary lung cancer (IPLC), especially in never smokers, its effect on SPLC risk is unknown.
METHODS: We identified 2439 IPLC patients from the UK Biobank, followed through 2017, linking baseline addresses to 2005-2007 annual average exposures of particulate matter (PM10) and nitrogen dioxide (NO2) from the EU-wide Land Use Regression model. Associations with SPLC risk were assessed using cause-specific Cox models adjusted for co-pollutants, socioeconomic factors, smoking, and tumour characteristics.
RESULTS: Of 2439 IPLC patients, 92 (3.7%) developed SPLC over 6561 person-years. The 10-year cumulative incidence of SPLC was 3.98% (3.11-4.85%). A dose-response relationship was observed between PM10 and SPLC risk, with an adjusted hazard ratio (aHR) of 6.43 (2.38-17.32) in the highest vs. lowest (aHR = 1.69 [0.68-4.19]) quintile; a co-pollutant NO2 showed an aHR of 0.96 (0.93-0.99). The PM10 effect was pronounced in never-smoking (aHR = 2.26 [1.22-4.18]) vs. ever-smoking IPLC patients (aHR = 1.42 [1.21-1.68]) on the risk of non-small cell SPLC.
INTERPRETATION: Exposure to PM10 may increase SPLC risk in lung cancer survivors, highlighting the potential value of incorporating environmental factors into SPLC surveillance to identify high-risk individuals.
METHODS: We identified 2439 IPLC patients from the UK Biobank, followed through 2017, linking baseline addresses to 2005-2007 annual average exposures of particulate matter (PM10) and nitrogen dioxide (NO2) from the EU-wide Land Use Regression model. Associations with SPLC risk were assessed using cause-specific Cox models adjusted for co-pollutants, socioeconomic factors, smoking, and tumour characteristics.
RESULTS: Of 2439 IPLC patients, 92 (3.7%) developed SPLC over 6561 person-years. The 10-year cumulative incidence of SPLC was 3.98% (3.11-4.85%). A dose-response relationship was observed between PM10 and SPLC risk, with an adjusted hazard ratio (aHR) of 6.43 (2.38-17.32) in the highest vs. lowest (aHR = 1.69 [0.68-4.19]) quintile; a co-pollutant NO2 showed an aHR of 0.96 (0.93-0.99). The PM10 effect was pronounced in never-smoking (aHR = 2.26 [1.22-4.18]) vs. ever-smoking IPLC patients (aHR = 1.42 [1.21-1.68]) on the risk of non-small cell SPLC.
INTERPRETATION: Exposure to PM10 may increase SPLC risk in lung cancer survivors, highlighting the potential value of incorporating environmental factors into SPLC surveillance to identify high-risk individuals.